Serum N-Glycomics analysis and HBV - Hepatology Jan.2026

Serum N-glycomics analysis refers to the study of N-linked glycans (complex sugar molecules attached to proteins) present in serum. This analytical approach focuses on profiling and identifying specific glycan structures that may be associated with various diseases, including hepatocellular carcinoma (HCC) linked to chronic hepatitis B virus (HBV) infection. N-glycomics analysis uses advanced techniques such as mass spectrometry and machine learning to quantify and characterize glycan patterns in biological samples.

How N-glycomics Analysis Helps in HCC Diagnosis in HBV Infection:

1. Enhanced Sensitivity and Specificity:

• Traditional diagnostic markers for HCC, such as alpha-fetoprotein (AFP) and Protein Induced by Vitamin K Absence or Antagonist-II (PIVKA-II), often lack sufficient sensitivity and specificity, particularly in early-stage HCC detection.
• N-glycomics analysis identifies unique glycan profiles associated with HCC, providing more accurate diagnostic models. In the study, machine learning-based models (Random Forest and Support Vector Machine) demonstrated significantly higher diagnostic accuracy with AUC values of 0.967 and 0.908, compared to AFP (0.687) and PIVKA-II (0.665).

2. Early Detection of HCC:

• N-glycomics models can detect HCC earlier than imaging techniques, which is crucial for timely intervention and improving patient outcomes.
• The study showed that the N-glycomics-based diagnostic models outperformed conventional markers in subgroup analyses and external validation, making them highly reliable for early screening.

3. Prognostic Value:

• Beyond diagnosis, N-glycomics analysis aids in monitoring disease progression and recurrence. The prognostic model (prog-G) developed in the study was able to predict recurrence in patients with HCC after curative treatment.
• During follow-up, the prog-G model identified all recurrent HCC cases before imaging findings, outperforming AFP and PIVKA-II. This capability allows for earlier therapeutic intervention to manage recurrence.

4. Precision Medicine:

• By leveraging N-glycomics profiling, clinicians can make more informed decisions tailored to individual patients. This promotes precision treatment strategies for HCC in HBV-infected individuals, improving overall clinical outcomes.

5. Non-Invasive and Scalable:

• Serum N-glycomics analysis is a non-invasive diagnostic method, making it suitable for routine clinical use and large-scale screening of at-risk populations, including those with chronic HBV-related cirrhosis.

Conclusion:

Serum N-glycomics analysis represents a promising advancement in the diagnosis and management of HCC in patients with HBV infection. By providing highly sensitive and specific models for early detection and recurrence monitoring, it addresses the limitations of conventional markers like AFP and PIVKA-II. The integration of N-glycomics into clinical practice has the potential to improve decision-making, enhance precision treatment, and ultimately reduce the global health burden of HBV-related HCC.